Premium
Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.
Author(s) -
Wanwimolruk S,
Chalcroft S
Publication year - 1991
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1991.tb03961.x
Subject(s) - debrisoquine , quinine , pharmacokinetics , pharmacology , biotransformation , chemistry , metabolism , medicine , cyp2d6 , biochemistry , enzyme , cytochrome p450 , malaria , immunology
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine after a single dose (600 mg) of quinine sulphate was studied in eight extensive metabolizers (EM) and five poor metabolizers (PM). The mean elimination half‐life of quinine in the PMs (10.2 +/‐ 1.6 (s.d.)h) was similar to that in the EMs (10.9 +/‐ 1.7 h). The oral clearance of quinine in the PM subjects was 0.092 +/‐ 0.021 l h‐1 kg‐1 and was not significantly different (P greater than 0.05) from that observed in the EM subjects (0.073 +/‐ 0.019 l h‐1 kg‐1). This suggests that even though quinine is extensively metabolized by oxidative biotransformation, this is carried out largely by P450 isoenzymes different from P450IID6 which oxidizes debrisoquine.